Prognostic Factors of Patients With COVID-19

SARS-CoV-2 Clinical Trial

Official title:

Prognostic Factors of Patients With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04292964
• Other study ID #: 2020-02-2
• Status: Completed
• Start date: March 1, 2020
• Est. completion date: March 13, 2020

Study information

• Verified date: March 2020
• Source: Chongqing Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. Despite lower mortality rate, SARS-CoV-2 has killed more people than SARS and MERS and the number keeps growing. Epidemic studies have been well described clinical features of patients with COVID-19, with the disease severity being an independent predictor of poor outcome. However, there is still no research investigating the prognostic factors of patients with COVID-19.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 201
• Est. completion date: March 13, 2020
• Est. primary completion date: March 13, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult aged >=18years old;

• Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral pneumonia.

• Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.

Exclusion Criteria:

• Near-death state (expected survival time less than 24 hours);

• Malignant tumor;

• Pregnancy or puerperium women;

• Patients who refused to participant.

Related Conditions & MeSH terms

• Outcome, Fatal
• SARS-CoV-2

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Chongqing Medical University	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Chongqing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all-cause mortality		30 days
Secondary	all-cause mortality		15 days
Secondary	Severe state	Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.	15 days